Andrew Srisuwananukorn, MD, of the Ohio State University Comprehensive Cancer Center, explained the potential of artificial intelligence (AI)-based support tools for differentiating primary myelofibrosis (prePMF) and essential thrombocythemia (ET) in the community setting.
An artificial intelligence (AI) model was able to differentiate between primary myelofibrosis (prePMF) and essential thrombocythemia (ET) with 92.3% accuracy by examining digital whole-slide images, according to a study presented at the 2023 American Society of Hematology Annual Meeting and Exposition.
AI-based decision support tools have potential to increase diagnostic accuracy for physicians in the community who may not see patients with prePMF or ET often, said Andrew Srisuwananukorn, MD, of Ohio State University Comprehensive Cancer Center, lead author of the study.
In this interview, Srisuwananukorn discussed the potential benefits and considerations for the development of AI algorithms to help diagnose these conditions.
Transcript
What is the potential value of implementing AI to assist in appropriately diagnosing patients with prePMF and ET in the clinical setting?
I view the benefit of a potential algorithm such as the one that we've created to be used ubiquitously across multiple centers. I find that the value of such a tool might be helpful in community practices that don't necessarily see myeloproliferative neoplasms on a consistent basis. These algorithms are cheap and affordable to be used and are equitable across different countries.
As AI use becomes more common, what can be done to ensure these algorithms are developed effectively and ethically?
I think there are 2 aspects that we really should be considering as we develop these AI algorithms. Number 1, it's important for us to understand that the algorithm was developed on a patient cohort, and we really want that patient cohort to be representative of the general population. It might accidentally learn a feature of the cohort that has no basis in biology, so it's important that our algorithm is representative of all patient cohorts of at-risk populations.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Mental Health Diagnoses, Care Challenges Rise Among US Youth, Report Finds
April 26th 2024While behavioral health care utilization has been rising, the treatment landscape has been worsening. New findings show that 20% of youths did not receive any form of treatment within 3 months of their initial behavioral health diagnosis.
Read More